Which antiarrhythmic agents are contraindicated in patients with structural heart disease (e.g., prior myocardial infarction, left ventricular systolic dysfunction, cardiomyopathy, significant left ventricular hypertrophy, or valvular disease)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antiarrhythmics Contraindicated in Structural Heart Disease

Class IC antiarrhythmic drugs (flecainide and propafenone) should not be used in patients with structural heart disease, including prior myocardial infarction, coronary artery disease, impaired left ventricular function, significant left ventricular hypertrophy, or moderate-to-severe valvular disease. 1

Primary Contraindications

Class IC Agents: Flecainide and Propafenone

  • Absolutely contraindicated in patients with:
    • Prior myocardial infarction
    • Coronary artery disease
    • Reduced left ventricular ejection fraction (HFrEF)
    • Severe left ventricular hypertrophy
    • Moderate or greater valvular heart disease 1, 2

These restrictions stem from increased proarrhythmic risk and potential for ventricular tachyarrhythmias in structural heart disease 3, 4. The evidence is consistent across multiple guidelines that these agents are safe only in patients without structural heart disease 5, 6.

Dronedarone

  • Contraindicated in:
    • NYHA Class III-IV heart failure 1, 7
    • Permanent atrial fibrillation (particularly with significant cardiovascular disease burden) 7
    • Unstable hemodynamic conditions
    • History of or current heart failure with left ventricular dysfunction 7

The ANDROMEDA and PALLAS trials demonstrated harm with dronedarone in patients with moderate-to-severe heart failure 7.

Safe Alternatives in Structural Heart Disease

When antiarrhythmic therapy is needed in patients with structural heart disease, the following agents are appropriate:

First-Line Options:

  • Amiodarone: The most broadly safe option across all forms of structural heart disease, including HFrEF, coronary disease, and significant LVH 1, 8, 6, 9
  • Beta-blockers: Reduce mortality in heart failure and post-MI patients 4, 10

Alternative Class III Agents:

  • Sotalol: Can be used in structural heart disease but requires monitoring for QT prolongation and torsades de pointes 5
  • Dofetilide: Acceptable in structural heart disease and coronary disease, but requires inpatient initiation with QT monitoring 5, 6

For Acute Management:

  • Ibutilide or procainamide (IV): May be considered for cardioversion in structural heart disease patients without hypotension or heart failure manifestations, with close monitoring for at least 6 hours 1

Clinical Algorithm for Drug Selection

Step 1: Assess for structural heart disease

  • Prior MI, CAD, LV dysfunction (any degree), significant LVH, or moderate+ valvular disease

Step 2: If structural heart disease is ABSENT:

  • Flecainide or propafenone are reasonable first-line options 1, 5, 9

Step 3: If structural heart disease is PRESENT:

  • Avoid flecainide and propafenone entirely
  • Use amiodarone as primary option 1, 8, 9
  • Consider sotalol or dofetilide as alternatives (with appropriate monitoring) 5

Step 4: If NYHA Class III-IV heart failure:

  • Avoid dronedarone
  • Use amiodarone or dofetilide only 7, 8, 7

Critical Pitfalls to Avoid

  1. Do not extrapolate "stable CAD" as safe for Class IC agents: Even stable coronary disease without recent MI remains a contraindication per current guidelines 1, 2, though emerging research suggests this may warrant reconsideration in highly selected cases 11, 12

  2. Do not use dronedarone in permanent AF: This is explicitly contraindicated regardless of other factors 7

  3. Do not combine dronedarone with digoxin: Increased sudden mortality signal in PALLAS trial 7

  4. Do not use Class IC agents with AV nodal blockers initially: Risk of 1:1 atrial flutter conduction; combine with beta-blockers or calcium channel blockers 1

The evidence base strongly supports these restrictions, with Class IC contraindications rooted in increased mortality demonstrated in the CAST trial and consistently reinforced across contemporary guidelines 3, 4, 10, 13.

References

Research

[Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].

Herzschrittmachertherapie & Elektrophysiologie, 2010

Research

Antiarrhythmic Drugs.

Current treatment options in cardiovascular medicine, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.